On September 4th, 2020, the Food and Drug Administration (FDA) approved Gavreto (pralsetinib) for the treatment of advanced non-small cell lung cancer (NSCLC) with tumors having changes in RET. The FDA based their approval on the results of the clinical trial ARROW which showed that patients receiving Gavreto (pralsetinib) had a high chance of responding well to treatment.

Gavreto (pralsetinib) being available as another targeted therapy option for RET positive NSCLC gives patients access to a wider variety or targeted therapies than were previously available. In addition, the FDA has approved the Oncomine Dx Target Test as a companion diagnostic for Gavreto.

Read the full FDA press release